Gamma-hydroxybutyric acid (GHB) is a psychoactive drug and a putative neurotransmitter, derived from gammaaminobutyric acid (GABA). At micromolar concentrations GHB binds to specific high and low affinity binding sites present in discrete areas of the brain, while at millimolar concentrations GHB also binds to GABA B receptors. Previous studies indicated that GHB inhibits bothGamma-hydroxybutyric acid (GHB) is a psychoactive drug and a putative neurotransmitter (Bernasconi et al. 1999;Maitre 1997). Administered peripherally, GHB penetrates freely into the brain and produces doserelated pharmacological effects including euphoria, antidepressant, and anxiolytic effects, sedation, sleep, anesthesia (Agabio and Gessa 2002;Colombo et al. 1998;De Couedic and Voisse 1964;Laborit et al. 1960;Rinaldi et al. 1967;Schmidt-Mutter et al. 1998). GHB has been used clinically as a general anesthetic and as a sleep inducer in the treatment of narcolepsy (Agabio and Gessa 2002;Broughton and Mamelak 1979). GHB is currently marketed in Italy and Austria for the treatment of alco- Gallimberti et al. 1989Gallimberti et al. , 2000. However, GHB has also gained popularity in the illicit market in the United States, being abused for its euphoriant action, which reportedly resembles that of alcohol and ecstasy (Boyce et al. 2000;Kam and Yoong 1998;Nicholson and Balster 2001). However, GHB is also synthesized and released by specific neurons in the brain and possesses most of the properties required to be classified as a neurotransmitter and/or neuromodulator. In fact, synthesis, release, uptake mechanisms, and specific binding sites for GHB have been identified in the mammalian brain (Benavides et al. 1982a,b;Hechler et al. 1985Hechler et al. , 1992Maitre et al. 1983;Rumigny et al. 1981;Snead and Liu 1984;Vayer et al. 1988). GHB binding sites exhibit high (Kd 30-580 nM) and low (about 20 M) affinity for GHB (Benavides et al. 1982a) and are sensitive to pertussis toxin, suggesting that these sites could represent G protein coupled receptors (Kemmel et al. 1998;Rotomponirina et al. 1995). GHB binding sites have a discrete brain distribution including the frontal cortex, nucleus accumbens, amygdala, hypothalamus, and, with highest density, the hippocampus (Hechler et al. 1992;Maitre et al. 2000;Snead et al. 1990). The synthetic structural analog of GHB, 6,7,8, (Maitre et al. 2000). In vivo, NCS-382 diminishes the sedative effect and the petit mal seizures induced by GHB (Hu et al. 2000;Schmidt et al. 1991;Schmidt-Mutter et al. 1998) and suppresses GHB-intravenous self-administration in mice (Martellotta et al. 1998). Moreover, NCS-382 inhibits GHB-induced increase in Guanosine 3 Ј ,5 Ј -cyclic monophosphate (cGMP) levels and inositol phosphate turnover in the hippocampus both in vivo and in vitro Snead 2000). At millimolar concentrations GHB displaces [ 3 H] baclofen from GABA B (gammaaminobutyric acid) receptors (Mathivet et al. 1997;Snead 1996). GHB action on GABA B receptors appears to mediate some of the pharmacological actions of GHB...